Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle

American Journal of Pathology

Volumn 177, Issue 1, 2010, Pages 291-299

  Draeger, Annette ^a   Sanchez Freire, Verónica ^a   Monastyrskaya, Katia ^a   Hoppeler, Hans ^a   Mueller, Matthias ^a   Breil, Fabio ^a   Mohaupt, Markus G ^b   Babiychuk, Eduard B ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANNEXIN; ATROGIN 1; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM CHANNEL L TYPE; CALCYCLIN; CALPAIN 1; CALPAIN 2; CALPAIN 3; CHOLESTEROL ACYLTRANSFERASE; COLLAGEN TYPE 1; CYTOCHROME C OXIDASE; DYSFERLIN; DYSTROPHIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; LIPOCORTIN 1; LIPOCORTIN 2; LIPOCORTIN 4; LIPOCORTIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR; MYOSIN HEAVY CHAIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RYANODINE RECEPTOR 1; RYANODINE RECEPTOR 3; SODIUM CALCIUM EXCHANGE PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; DRUG INDUCED MYOPATHY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; MUSCLE BIOPSY; MUSCLE CELL; MYOPATHY; PRIORITY JOURNAL; SKELETAL MUSCLE; TISSUE REPAIR; UPREGULATION;

EID: 77954592533     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091140     Document Type: Article

References (40)

1. Harper CR, Jacobson TA: The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007, 18:401-408
2. Sathasivam S, Lecky B: Statin induced myopathy. BMJ 2008, 337: a2286. doi: 10.1136/bmj.a2286.:a2286
3. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003, 289:1681-1690
4. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -the PRIMO Study. Cardiovasc Drugs Ther 2005, 19:403-414
5. Sinzinger H, Wolfram R, Peskar BA: Muscular side effects of statins. J Cardiovasc Pharmacol 2002, 40:163-171
6. Ansell BJ, Fonarow GC, Maki KC, Dicklin MR, Bell M, Davidson MH: Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J 2006, 152:976-981
7. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R: SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008, 359:789-799
8. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609-1616
9. Morikawa S, Murakami T, Yamazaki H, Izumi A, Saito Y, Hamakubo T, Kodama T: Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb 2005, 12: 121-131
10. Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M: Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther 2005, 314:1032-1041
11. Yu JG, Sewright K, Hubal MJ, Liu JX, Schwartz LM, Hoffman EP, Clarkson PM: Investigation of gene expression in C(2)C(12) myotubes following simvastatin application and mechanical strain. J Atheroscler Thromb 2009, 16:21-29
12. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD: Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005, 25:2560-2566
13. Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, Hoppeler H, Breil F, Draeger A: Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009, 181:E11-E18
14. Langer T, Levy RI: Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 1968, 279:856-858
15. Gharavi AG, Diamond JA, Smith DA, Phillips RA: Niacin-induced myopathy. Am J Cardiol 1994, 74:841-842
16. Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP: Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993, 33:226-229 (Pubitemid 23129500)
17. Mueller M, Breil FA, Vogt M, Steiner R, Lippuner K, Popp A, Klossner S, Hoppeler H, Dapp C: Different response to eccentric and concentric training in older men and women. Eur J Appl Physiol 2009, 107:145-153
18. Thompson PD, Clarkson PM, Rosenson RS: An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97:69C-76C
19. Bergstrom J: Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest 1975, 35:609-616
20. Zaugg P, Djonov V, Füchtbauer EM, Draeger A: Sorting of murine vascular smooth muscle cells during wound healing in the chicken chorioallantoic membrane. Exp Cell Res 1999, 253:599-606 (Pubitemid 30003121)
21. Draeger A, Monastyrskaya K, Burkhard FC, Wobus AM, Moss SE, Babiychuk EB: Membrane segregation and downregulation of raft markers during sarcolemmal differentiation in skeletal muscle cells. Dev Biol 2003, 262:324-334 (Pubitemid 37194511)
22. Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, Allemann C, Babiychuk E: Statin therapy induces ultra-structural damage in skeletal muscle in patients without myalgia. J Pathol 2006, 210:94-102 (Pubitemid 44288185)
23. Glover L, Brown RH Jr: Dysferlin in membrane trafficking and patch repair. Traffic 2007, 8:785-794 (Pubitemid 46971627)
24. Moosmann B, Behl C: Selenoprotein synthesis and side-effects of statins. The Lancet 2004, 363:892-894
25. Hanai J, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, Lecker SH: The musclespecific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007, 117:3940-3951
26. Mallinson JE, Constantin-Teodosiu D, Sidaway J, Westwood FR, Greenhaff PL: Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol 2009, 587:219-230
27. Franzini-Armstrong C: Architecture and regulation of the Ca2+ delivery system in muscle cells. Appl Physiol Nutr Metab 2009, 34:323-327
28. Guis S, Figarella-Branger D, Mattei JP, Nicoli F, Le Fur Y, Kozak-Ribbens G, Pellissier JF, Cozzone PJ, Amabile N, Bendahan D: In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum 2006, 55:551-557
29. Liantonio A, Giannuzzi V, Cippone V, Camerino GM, Pierno S, Camerino DC: Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system. J Pharmacol Exp Ther 2007, 321:626-634
30. Lamb GD, Junankar PR, Stephenson DG: Raised intracellular [Ca2+] abolishes excitation-contraction coupling in skeletal muscle fibres of rat and toad. J Physiol 1995, 489:349-362
31. Verburg E, Murphy RM, Richard I, Lamb GD: Involvement of calpains in Ca2+-induced disruption of excitation-contraction coupling in mammalian skeletal muscle fibers. Am J Physiol Cell Physiol 2009, 296:C1115-C1122
32. Han R, Campbell KP: Dysferlin and muscle membrane repair. Curr Opin Cell Biol 2007, 19:409-416
33. Piccolo F, Moore SA, Ford GC, Campbell KP: Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb-girdle muscular dystrophies. Ann Neurol 2000, 48:902-912
34. McNeil AK, Rescher U, Gerke V, McNeil PL: Requirement for annexin A1 in plasma membrane repair. J Biol Chem 2006, 281:35202-35207
35. Babiychuk EB, Monastyrskaya K, Potez S, Draeger A: Intracellular Ca(2+) operates a switch between repair and lysis of streptolysin O-perforated cells. Cell Death Differ 2009, 16:1126-1134
36. Golomb BA, Evans MA: Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008, 8:373-418
37. van Vliet AK, Negre-Aminou P, van Thiel GC, Bolhuis PA, Cohen LH: Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle. Biochem Pharmacol 1996, 52:1387-1392
38. Kaufmann P, Torok M, Zahno A, Waldhauser KM, Brecht K, Krahenbuhl S: Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 2006, 63:2415-2325
39. Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC: Statininduced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005, 33:246-257
40. Laaksonen R, Katajamaa M, Paiva H, Sysi-Aho M, Saarinen L, Junni P, Lutjohann D, Smet J, Van Coster R, Seppanen-Laakso T, Lehtimaki T, Soini J, Oresic M: A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 2006, %20,1:e97